What is the best treatment for children with limited-stage Hodgkin lymphoma?

Current Hematologic Malignancy Reports

Volumn 4, Issue 3, 2009, Pages 129-135

  Keller, Frank G ^a   Castellino, Sharon M ^a   Nachman, James B ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

BONE GROWTH; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CERVICAL LYMPHADENOPATHY; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENDOCRINE DISEASE; EVENT FREE SURVIVAL; HODGKIN DISEASE; HUMAN; LAPAROTOMY; LUNG DISEASE; LYMPHADENOPATHY; LYMPHANGIOGRAPHY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; RISK ASSESSMENT; SPLENECTOMY; SYMPTOMATOLOGY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 67650099871     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0019-0     Document Type: Review

References (37)

1. Ng AK, Mauch PM: Radiation therapy in the treatment of hematologic malignancies. In Hematology: Basic Principles and Practice. Edited by Hoffman R, Benz EJ, Shattil SJ, et al. Philadelphia: Churchill Livingstone Elsevier; 2009:899-907.
2. Pobert JC, Parker BR: Growth retardation in children after megavoltage irradiation of the spine. Cancer 1973, 32:634-639.
3. Willman KY, Cox RS, Donaldson SS: Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 1993, 28:85-92.
4. Schellong G: The balance between cure and late effects in childhood Hodgkin's lymphoma: The experience of the German-Austrian Study Group since 1978. Ann Oncol 1996, 7(Suppl 4): S67-S72.
5. Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334:745-751.
6. Constine LS, Donaldson SS, McDougall IR, et al.: Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 1984, 53:878-883.
7. Mefferd JM, Donaldson SS, Link MP: Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989, 679-685.
8. Robison LL, Bhatia S: Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003, 122:345-359.
9. Chow LM, Nathan PC, Hodgson DC, et al.: Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006, 24:5735-5741.
10. Stein H, Delsol G, Pileri S, et al.: Hodgkin lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon, France: IARC Press; 2001:237-253.
11. Percy CL, Smith MA, Linet L, et al.: Lymphomas and reticuloendothelial neoplasms. In Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Edited by Ries LAG, Smith MA, Gurney JG, et al. Bethesda, MD: National Cancer Institute; 1999:35-49.
12. Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002, 20:3765-3771.
13. Ruhl U, Albrecht M, Dieckmann K, et al.: Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001, 51:1209-1218.
14. Donaldson SS, Link M, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007, 25:332-337.
15. Vecchi V, Pileri S, Burnelli R, et al.: Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 1993, 72:2049-2057.
16. O'Leary M, Sheaffer J, Keller FG, et al.: Lymphomas and reticuloendothelial neoplasms. In Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767. Edited by Bleyer A, O'Leary M, Barr R, Ries LAG. Bethesda, MD: National Cancer Institute; 2006:25-38.
17. Landman-Parker J, Pacquement H, Leblanc T, et al.: Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy - results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000, 18:1500-1507.
18. Kostakoglu L, Coleman M, Leonard JP, et al.: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002, 43:1018-1027.
19. Torizuka T, Nakamura F, Kanno T, et al.: Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004, 31:22-28.
20. Hutchings M, Mikhaeel NG, Fields PA, et al.: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005, 16:1160-1168.
21. Hutchings M, Loft A, Hansen M, et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
22. Gallamini A, Rigacci L, Merli F, et al.: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91:475-481.
23. Zinzani PL, Tani M, Fanti S, et al.: Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 2006, 17:1296-1300.
24. Querellou S, Valette F, Bodet-Milin C, et al.: FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006, 85:759-767.
25. Kostakoglu L, Goldsmith SJ, Leonard JP, et al.: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006, 107:2678-2687.
26. Gallamini A, Hutchings M, Rigacci L, et al.: Early interim 2(18F)fluoro-2-deoxy-D glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
27. KungAFH, Schwartz CL, Ferree CR, et al.: POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 2006, 28:362-368.
28. Schellong G, Potter R, Bramswig J, et al.: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999, 17:3736-3744.
29. Shankar AG, Ashley S, Atra A, et al.: A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease. Eur J Cancer 1998, 34:2058-2063.
30. Yaniv I, Saab A, Cohen RJ, et al.: Hodgkin disease in children: reduced tailored chemotherapy for stage I-II disease. J Pediatr Hematol Oncol 1996, 18:76-80.
31. Körholz D, Claviez A, Hasenclever D, et al.: The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004, 216:150-156.
32. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al.: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European Network Group on Pediatric Hodgkin Lymphoma. Cancer 2007, 110:179-185.
33. Karayalcin G, Behm FG, Gieser PW, et al.: Lymphocyte predominant Hodgkin disease: Clinico-pathologic features and results of treatment - the Pediatric Oncology Group experience. Med Pediatr Oncol 1997, 29:519-525.
34. Murphy SB, Morgan ER, Katzenstein HM, et al.: Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003, 25:684-687.
35. Sandoval C, Venkateswaran L, Billups C, et al.: Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002, 24:269-273.
36. Mertens AC, Mitby PA, Radloff G, et al.: XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 2004, 101:1463-1472.
37. Cheson BD, Pfistner B, Juweid ME, et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25: 579-586.